The MERIT study evaluated maraviroc versus efavirenz, both with zidovudine/lamivudine, in treatment-naïve patients with CCR5-tropic (R5) HIV-1. Post hoc analyses previously assessed week 48 outcomes in patients rescreened with R5 virus by a more sensitive tropism assay.Week 96 efficacy (post hoc, n = 614) and safety (n = 721) were assessed.Proportions of subjects <50 copies/mL (58.8\% maraviroc, 62.7\% efavirenz) and time to loss of virologic response (TLOVR) responders (<50 copies/mL: 60.5\% vs 60.7\%) were similar. Maraviroc recipients had greater CD4 increases (+ 212 vs + 171 cells/mm(3)) and fewer adverse event discontinuations (6.1\% vs 15.5\%), malignancies, and category C events.Week 96 data confirm week 48 observations in MERIT.
Efficacy and safety of maraviroc versus efavirenz, both with zidovudine/lamivudine: 96-week results from the MERIT study.
DI PERRI, Giovanni;
2010-01-01
Abstract
The MERIT study evaluated maraviroc versus efavirenz, both with zidovudine/lamivudine, in treatment-naïve patients with CCR5-tropic (R5) HIV-1. Post hoc analyses previously assessed week 48 outcomes in patients rescreened with R5 virus by a more sensitive tropism assay.Week 96 efficacy (post hoc, n = 614) and safety (n = 721) were assessed.Proportions of subjects <50 copies/mL (58.8\% maraviroc, 62.7\% efavirenz) and time to loss of virologic response (TLOVR) responders (<50 copies/mL: 60.5\% vs 60.7\%) were similar. Maraviroc recipients had greater CD4 increases (+ 212 vs + 171 cells/mm(3)) and fewer adverse event discontinuations (6.1\% vs 15.5\%), malignancies, and category C events.Week 96 data confirm week 48 observations in MERIT.
I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.
